Characterization of protein unable to bind von Willebrand factor in recombinant factor VIII products.

Autor: Chun H; Center for Biologics Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, MD, USA., Pettersson JR; Center for Biologics Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, MD, USA., Shestopal SA; Center for Biologics Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, MD, USA., Wu WW; Center for Biologics Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, MD, USA., Marakasova ES; Center for Biologics Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, MD, USA., Olivares P; Center for Biologics Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, MD, USA., Surov SS; Center for Biologics Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, MD, USA., Ovanesov MV; Center for Biologics Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, MD, USA., Shen RF; Center for Biologics Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, MD, USA., Sarafanov AG; Center for Biologics Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, MD, USA.
Jazyk: angličtina
Zdroj: Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2021 Apr; Vol. 19 (4), pp. 954-966. Date of Electronic Publication: 2021 Feb 24.
DOI: 10.1111/jth.15257
Abstrakt: Background: Therapeutic products with coagulation factor VIII (FVIII) have a wide range of specific activities, implying presence of protein with altered structure. Previous studies showed that recombinant FVIII products (rFVIII) contain a fraction (FVIII FT ) unable to bind von Willebrand factor (VWF) and reported to lack activity. Because of loss of function(s), FVIII FT can be defined as a product-related impurity, whose properties and levels in rFVIII products should be investigated.
Objective: To isolate and characterize the FVIII FT fraction in rFVIII products.
Methods: Protein fractions unable (FVIII FT ) and able (FVIII EL ) to bind VWF were isolated from rFVIII products using immobilized VWF affinity chromatography (IVAC) and characterized by gel electrophoresis, immunoblotting, FVIII activity test, surface plasmon resonance, mass spectrometry, and for plasma clearance in mice.
Results and Conclusions: A robust IVAC methodology was developed and applied for analysis of 10 rFVIII products marketed in the United States. FVIII FT was found at various contents (0.4%-21.5%) in all products. Compared with FVIII EL , FVIII FT had similar patterns of polypeptide bands by gel electrophoresis, but lower functional activity. In several representative products, FVIII FT was found to have reduced sulfation at Tyr1680, important for VWF binding, decreased interaction with a low-density lipoprotein receptor-related protein 1 fragment, and faster plasma clearance in mice. These findings provide basic characterization of FVIII FT and demonstrate a potential for IVAC to control this impurity in rFVIII products to improve their efficacy in therapy of hemophilia A.
(Published 2021. This article is a U.S. Government work and is in the public domain in the USA.)
Databáze: MEDLINE
Externí odkaz: